Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.52 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.52 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 18/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.49 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19384679 | 1.00 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20305074 | 0.99 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| Hydrochloric Acid SCHEMBL20305071 | 0.99 | ITGAV (0.51) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL20158336 | 0.92 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL20158231 | 0.91 | ITGAV (0.53) | ITGAVITGB6ITGB3ITGB5ITGB1 | |
| SCHEMBL21767652 | 0.90 | ITGAV (0.53) | ITGAVITGB6ITGB3ITGB5 | |
| SCHEMBL21767649 | 0.90 | ITGAV (0.53) | ITGAVITGB6ITGB3ITGB5 | |
| Hydrochloric Acid SCHEMBL21767712 | 0.89 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5 | |
| Hydrochloric Acid SCHEMBL21774677 | 0.89 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5 | |
| Hydrochloric Acid SCHEMBL21767715 | 0.89 | ITGAV (0.52) | ITGAVITGB6ITGB3ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20210122747-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-04-29 | — | — | US | disclosed |
| US-10696672-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3197894-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| EP-3197894-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-03 | — | — | EP | disclosed |
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| CN-107074851-B | As αvβ6Naphthyridine derivatives of integrin antagonists for the treatment of e.g. fibrotic diseases | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-10513517-B2 | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-12-24 | — | — | US | disclosed |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016046230-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10513517-B2 | Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases | ITGB1, ITGB3, ITGA1 | ITGAV 4/4885ITGB6 12/4885ITGB3 2/4885 |
| US-20170291899-A1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF E.G. FIBROTIC DISEASES | ITGB1, ITGB3, ITGA1 | ITGAV 4/4885ITGB6 13/4885ITGB3 2/4885 |
| US-10696672-B2 | Amino acid compounds and methods of use | ITGB6, ITGA6, ITGA5 | ITGAV 4/4885ITGB6 1/4885ITGB3 13/4885 |
| US-20210122747-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB6 1/4885ITGB3 13/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | ITGAV 5/4885ITGB6 1/4885ITGB3 8/4885 |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | ITGAV, ITGB6, ITGB1 | ITGAV 1/4885ITGB6 2/4885ITGB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.